{"entity":{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","aka":[],"tldr":"Leads breast medical oncology at Samsung Medical Center and has driven Korean participation in the HER2 and CDK4/6 trials that changed practice.","summary":"Yeon Hee Park is Professor of Medical Oncology at Samsung Medical Center in Seoul, where she leads the breast cancer programme. She has driven Korean participation in the HER2 and CDK4/6 trials that changed practice, contributing to the trastuzumab deruxtecan, palbociclib and ribociclib programmes and to Korean genomic cohorts of young-onset breast cancer. Her publications include the Young-PEARL trial of palbociclib plus exemestane with a GnRH agonist against capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer. Her interests are HER2-positive disease, young-onset breast cancer and endocrine therapy.","asOf":"2026-09-08","links":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20YH%5BAuthor%5D%20Samsung%20Medical%20Center%20breast"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2","cdk4-6"],"drugs":["palbociclib","trastuzumab-deruxtecan"],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; breast cancer programme","institutionId":"samsung-medical-center","specialisms":["Breast cancer","HER2-positive disease","Young-onset breast cancer","Endocrine therapy"],"profiles":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20YH%5BAuthor%5D%20Samsung%20Medical%20Center%20breast"}],"papers":[{"title":"Palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal HR+ metastatic breast cancer (Young-PEARL)","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(19)30565-0"},{"title":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2115022","doi":"10.1056/NEJMoa2115022"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"},{"title":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112651","doi":"10.1056/NEJMoa2112651"}]},"route":"/people/park-yeon-hee/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/"}],"paper":[{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/"},{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/"},{"id":"paper-keynote-522-nejm-2022","kind":"paper","name":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","route":"/key-papers/paper-keynote-522-nejm-2022/"}]}}